Published online before print May 13, 2004, doi: 10.1161/01.STR.0000129790.00318.a3
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1636.)
© 2004 American Heart Association, Inc.
Original Contributions |
Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis
From the Vascular Biology Unit, James Cook University, Townsville, Queensland, Australia.
Correspondence to Assoc Prof Jonathan Golledge, Director, The Vascular Biology Unit, James Cook University, Townsville, Queensland 4811, Australia. E-mail Jonathan.Golledge{at}jcu.edu.au
Background and Purpose— The aim of this study was to compare the concentration of osteoprotegerin (OPG), receptor activator of nuclear factor 
B ligand (RANKL), and osteopontin (OPN) in stable (asymptomatic) and unstable (symptomatic) carotid atherosclerosis. In addition, we were interested in the effect of angiotensin II blockade on the secretion of these proteins by unstable atherosclerosis.
Methods— Endarterectomy samples removed from patients with recent (within 6 weeks) or no previous focal neurological symptoms were assessed by immunohistochemistry, Western analysis, and explant culture. Concentrations of OPG, RANKL, and OPN were measured by mean optical density (MOD), densitometry of protein bands, and enzyme-linked immunosorbent assay of supernatants from explant culture, and compared between symptomatic and asymptomatic patients.
Results— The concentration of OPG and OPN within the proximal internal carotid (PIC) part of the endarterectomy specimen removed from symptomatic patients was elevated 2- and 4-fold, respectively. Although the concentration of RANKL did not differ according to patients’ symptoms, the quantity of OPG secreted by explants of the PIC was greater in explants from symptomatic patients and could be significantly reduced within 48 hours of incubation with the angiotensin II blocker irbesartan.
Conclusion— OPG and OPN are upregulated in symptomatic human carotid atherosclerosis with possible implications for plaque stability. Angiotensin II blockade is able to downregulate OPG secretion in vitro.
Key Words: carotid arteries • atherosclerosis • carotid artery plaque
This article has been cited by other articles:
 |
|
 |
|
  S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kiechl, G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease Circulation, July 24, 2007; 116(4): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, S. Mangan, and P. Clancy Effects of Peroxisome Proliferator-Activated Receptor Ligands in Modulating Tissue Factor and Tissue Factor Pathway Inhibitor in Acutely Symptomatic Carotid Atheromas Stroke, May 1, 2007; 38(5): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, J. Muller, N. Shephard, P. Clancy, L. Smallwood, C. Moran, A. E. Dear, L. J. Palmer, and P. E. Norman Association Between Osteopontin and Human Abdominal Aortic Aneurysm Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 655 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Bennett, M. Scatena, E. A. Kirk, M. Rattazzi, R. M. Varon, M. Averill, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2117 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Brenner, J. Labreuche, P.-J. Touboul, K. Schmidt-Petersen, O. Poirier, C. Perret, J. Schonfelder, C. Combadiere, M. Lathrop, F. Cambien, et al. Cytokine Polymorphisms Associated With Carotid Intima-Media Thickness in Stroke Patients Stroke, July 1, 2006; 37(7): 1691 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, L. Jones, L. Oliver, F. Quigley, and M. Karan Folic Acid, Vitamin B12, MTHFR Genotypes, and Plasma Homocysteine. Clin. Chem., June 1, 2006; 52(6): 1205 - 1206. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Minoretti, C. Falcone, M. Calcagnino, E. Emanuele, M. P. Buzzi, E. Coen, and D. Geroldi Prognostic significance of plasma osteopontin levels in patients with chronic stable angina Eur. Heart J., April 1, 2006; 27(7): 802 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Sandberg, A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A.-K. L. Robertson, F. Muller, A. G. Semb, H. Scholz, et al. Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 857 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Higgins, S. A. Marvel, and J. D. Morrisett Quantification of Calcification in Atherosclerotic Lesions Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1567 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Moran, M. McCann, M. Karan, P. Norman, N. Ketheesan, and J. Golledge Association of Osteoprotegerin With Human Abdominal Aortic Aneurysm Progression Circulation, June 14, 2005; 111(23): 3119 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagasaki, M. Inaba, S. Jono, Y. Hiura, H. Tahara, K. Shirakawa, N. Onoda, T. Ishikawa, E. Ishimura, and Y. Nishizawa Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function Eur. J. Endocrinol., March 1, 2005; 152(3): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Demer and M. Abedin Skeleton key to vascular disease J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1977 - 1979. [Full Text] [PDF]
|
|